Hormone Therapy News

WASHINGTON — In postmenopausal women with vulvar and vaginal atrophy, ospemifene showed higher responder rates than placebo in two phase 3 randomized trials and offered relief from symptoms, according to data presented at the 25th annual meeting of The North American Menopause Society.

Paroxetine administered in low doses to treat vasomotor symptoms associated with menopause did not yield significant changes in body weight or sexual function, according to pooled phase 3 results published in Menopause.

WASHINGTON — Endogenous sex hormones were associated with ectopic cardiovascular fat volumes in women during varying stages of menopause, according to data presented at the 25th annual meeting of The North American Menopause Society.

WASHINGTON — Using DXA to determine body fat percentage expressed as a percentile for age and sex may be a reasonable, safe and simple approach to evaluate patients’ metabolic health, according to data presented at the 25th annual meeting of The North American Menopause Society.

Growth hormone replacement therapy provided sustained improvement in quality of life for adults and children with deficiencies, according to research published in The Journal of Clinical Endocrinology & Metabolism.

The FDA has approved a 33% smaller dose of the estradiol transdermal system for the prevention of postmenopausal osteoporosis, according to the manufacturer.

COLLEGE PARK, MD — On day 2 of a joint meeting on testosterone replacement therapies, the Bone, Reproductive and Urologic Drugs and Drug Safety and Risk Management FDA advisory committees voted 12-8, with one abstention, that a novel oral testosterone undecanoate did show efficacy as a testosterone replacement therapy.

COLLEGE PARK, MD — Two FDA advisory committees voted 20-1 in favor of revising the current indication for testosterone replacement therapies following several hours of charged presentations by clinicians, industry representatives and the public at a joint meeting Wednesday.

After a debate-filled meeting today, the Endocrinologic and Metabolic Drugs Advisory Committee voted 8 to 5 in favor of approval for recombinant human parathyroid hormone, rhPTH I-84, to be known as Natpara, for long-term management of hypoparathyroidism.

Women with greater diversity of gut microbiota appear to have an elevated urinary ratio of hydroxylated estrogen metabolites to parent estrogen, according to research published in The Journal of Clinical Endocrinoloty & Metabolism.